Chimerix soars on plans to submit application for US FDA accelerated approval for its brain tumor drug

Chimerix

09/12/2024 22:10

** Shares of biotech Chimerix  CMRX.O  rise 171.68% to $2.35
after the bell
    ** Company plans to submit an application seeking FDA's
accelerated approval in the U.S. for its drug dordaviprone as a
treatment for a type of glioma before year-end
    ** Adds it will be ready for a U.S. launch as early as Q3
2025
    ** CMRX is seeking approval of dordaviprone as a treatment
for recurrent H3 K27M-mutant diffuse glioma, a type of tumor
that forms in the brain
    ** Up to last close, stock down ~10% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com))